Free Trial
NASDAQ:IAM

Iambic Therapeutics Q3 2026 Earnings Results & Report

Iambic Therapeutics logo
$11.55 -1.55 (-11.83%)
As of 10:44 AM Eastern

Iambic Therapeutics missed analyst earnings expectations in its Q3 2026 results, released November 16, 2026. The company reported EPS of -$6.23 versus the -$0.33 consensus estimate.

Earnings Announcement Details

Quarter
Q3 2026
Time
Before Market Opens
Conference Call
8:00 AM ET

Iambic Therapeutics EPS Results

Actual EPS
-$6.23
Consensus EPS
-$0.33
Beat/Miss
Missed by -$5.90
One Year Ago EPS
N/A

Iambic Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Earnings Documents

Iambic Therapeutics Q3 2026 Earnings FAQ

Iambic Therapeutics (NASDAQ:IAM) reported earnings of -$6.23 per share for Q3 2026, missing the consensus estimate of -$0.33. The report was announced on Monday, November 16, 2026.

Iambic Therapeutics Earnings Headlines

Citigroup Begins Coverage on Iambic Therapeutics (NASDAQ:IAM)
Every Starlink dish pays this stock
There's a chip inside every Tesla and Starlink dish that Elon doesn't own. He pays royalties to use it. Now he's filed to launch 1,000,000 AI satellites, a move Dylan believes could mean a 100X bigger royalty bill starting December 8th. This free pick names the public company collecting on every unit.tc pixel
See More Iambic Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Iambic Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Iambic Therapeutics and other key companies, straight to your email.

About Iambic Therapeutics

Iambic Therapeutics (NASDAQ:IAM) is a biotechnology company that uses artificial intelligence and computational methods to discover and develop medicines. Its approach combines machine-learning tools with laboratory research to identify potential drug candidates and guide their design.

The company’s pipeline includes IAM1363, an investigational, brain-penetrant HER2 inhibitor being developed for cancers driven by HER2, including cancers that may spread to the brain. Iambic’s broader work focuses on advancing drug candidates generated through its technology platform.

View Iambic Therapeutics Profile